Advertisement
Journal Home
Search for

Volume 39, Issue 9, Pages 1259-1263 (June 2003)


View previous. 12 of 24 View next.

Development of an EORTC disease-specific quality of life questionnaire for use in patients with liver metastases from colorectal cancer

on behalf of the EORTC Quality of Life GroupV. Kavadasa, J.M. BlazebyaCorresponding Author Informationemail address, T. Conroyb, O. Sezerc, B. Holznerd, M. Kollere, J. Buckelsf

Received 12 December 2002; accepted 18 February 2003.

Abstract 

Quality of life (QL) is an important outcome measure within clinical trials. This paper describes the development of a QL module for patients with liver metastases from colorectal cancer (CRC) to supplement the European Organization for Research and Treatment of Cancer (EORTC) core QL questionnaire, the EORTC QLQ-C30. Phases 1–3 of the EORTC QL Group guidelines for developing QL modules were followed. The literature search generated 71 QL issues. Semi-structured interviews with eight healthcare professionals and 47 patients from the United Kingdom, France, Germany and Austria reduced the list to 23 issues. Questionnaire items were formulated to be compatible with the EORTC QLQ-C30. The provisional module was further tested in 102 patients resulting in a 21-item module, the QLQ-LMC21 (Liver Metastases Colorectal). A combination of the core questionnaire and the QLQ-LMC21 will provide essential QL information regarding the use of treatments in both the curative and palliative settings.

a University Division of Surgery, Level 7, Bristol Royal Infirmary, Bristol BS2 8HW, UK

b Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France

c Department of Oncology and Haematology, University Hospital Charité, Berlin, Germany

d Department of Biological Psychiatry, University Clinics Innsbruck, Innsbruck, Austria

e Institute of Theoretical Surgery, Philipps-University Marburg, Marburg, Germany

f Liver Unit, Queen Elizabeth Hospital, Birmingham, UK

Corresponding Author InformationCorresponding author. Tel.: +44-117-928-2336; fax: +44-117-925-2736

PII: S0959-8049(03)00236-3

doi:10.1016/S0959-8049(03)00236-3


View previous. 12 of 24 View next.